ArticleArchives of internal medicine research2026
Neuroprotective Role of DING Protein in Normal Aging and Alzheimer's Disease.
Article in Archives of internal medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Introduction: Previously, we showed that the phosphatase DING extracted from St. John's wort (p38SJ) is neuroprotective against EtOH-mediated toxicity in rat and human fetal neurons in vitro. Now, we assess the role of human DING in Alzheimer's disease (AD). DING (p38SJ/p38hu), a member of the DING family of proteins, has been shown to be neuroprotective against cellular stress injury induced by alcohol, HIV-1, and in cancer cells. DING has demonstrated phosphatase activity on MAPK substrates, but its effect on Tau phosphorylation, which is involved in AD, has not yet been explored. Methods: Expression of DING protein levels was studied in human postmortem brain using histochemistry and quantitative western blot with ANOVA. Five patients with dementia, of whom 3 had AD neuropathology, a fourth had AD/Parkinson complex, and one had cerebrovascular dementia, were compared with 5 non-dementia controls. Results: DING was present in the neuronal cell bodies and processes of both normal and AD-affected human brain tissue. DING demonstrated phosphatase activity in PC12 cells (a cell line derived from rat pheochromocytoma) and inhibited Tau phosphorylation in these cells and in human brain tissue (both normal and AD). Increasing DING by transduction and overexpression in PC12 cells was associated with increased cell survival. In human brains (age=72-92 years), levels of endogenously expressed 38 kDa DING protein correlated positively with Tau dephosphorylation. Conclusions: Excess Tau phosphorylation leads to the formation of neurofibrillary tangles in neurons, a hallmark of neurodegeneration in Alzheimer's disease. DING inhibits Tau phosphorylation and increases cell viability in non-proliferating neuronal cells overexpressing Tau, while reducing the viability of proliferating cells. Thus, DING may be neuroprotective in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.